Literature DB >> 2891151

Alpha 2-adrenoceptor antagonists and male sexual behavior: I. Mating behavior.

E R Smith1, R L Lee, S L Schnur, J M Davidson.   

Abstract

Three alpha 2-adrenoceptor antagonists yohimbine, idazoxan, and imiloxan were compared by examining the effects of a single injection on male rat copulatory behavior. Dose ranges were: yohimbine: 0.25-8.0 mg/kg; idazoxan: 0.25-8.0 mg/kg; imiloxan: 12.5-50.0 mg/kg. Yohimbine and idazoxan administration produced significant increases in the number of animals copulating to ejaculation and all three drugs increased the rate of copulation as evidenced by reductions in ejaculation latency and intercopulatory interval. Only yohimbine significantly reduced mount latency and postejaculatory interval, but yohimbine and imiloxan significantly reduced intromission latency and idazoxan showed a similar trend. The highest yohimbine dose suppressed sexual activity. A time-course experiment with yohimbine (2.0 mg/kg) and idazoxan (4.0 mg/kg) showed stimulation at 75 min and a trend at 5. To further explore the arousal-stimulating capacity of the two more effective drugs, a mounting test with genital anesthetization was used. Yohimbine but not idazoxan showed marked increases in mounting at 1.0-4.0 mg/kg. Both drugs had a suppressive effect at the highest doses. These data support the involvement of alpha 2-adrenoceptors in the regulation of male sexual behavior, specifically by facilitating sexual arousal, with no effects on ejaculatory threshold, as measured by intromission frequency. Yohimbine is the most globally effective agent and it is likely that factors other than yohimbine's alpha 2-antagonism may play a role in its unique, consistent and broad behavioral effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891151     DOI: 10.1016/0031-9384(87)90123-5

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  12 in total

1.  Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction.

Authors:  K Mann; T Klingler; S Noe; J Röschke; S Müller; O Benkert
Journal:  Arch Sex Behav       Date:  1996-02

Review 2.  Spinal control of penile erection.

Authors:  O Rampin; J Bernabé; F Giuliano
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

3.  Effects of antisense to the (alpha)2A-adrenoceptors administered into the region of the locus ceruleus on behaviors in plus-maze and sexual behavior tests in sham-operated and castrated male rats.

Authors:  G T Shishkina; T S Kalinina; N Y Sournina; N N Dygalo
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 4.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

5.  Opioid antagonists and the sexual satiation phenomenon.

Authors:  G Rodríguez-Manzo; A Fernández-Guasti
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

6.  Assessment of erectogenic properties of apomorphine and yohimbine in man.

Authors:  P Danjou; L Alexandre; D Warot; L Lacomblez; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 7.  Sexual behavior in male rodents.

Authors:  Elaine M Hull; Juan M Dominguez
Journal:  Horm Behav       Date:  2007-04-19       Impact factor: 3.587

8.  Influence of mirtazapine on the sexual behavior of male rats.

Authors:  Augusta Benelli; Claudio Frigeri; Alfio Bertolini; Susanna Genedani
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

9.  Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197).

Authors:  D Tallentire; G McRae; M Spedding; R Clark; B Vickery
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 10.  Central nervous system agents in the treatment of erectile dysfunction: how do they work?

Authors:  J Allard; F Giuliano
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.